argenx BV to acquire Forte Biosciences, Inc.

argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing the US headquartered firm entirely for cash. This acquisition marks a significant consolidation within the healthcare sector, bringing the target under full ownership of the buyer. The deal structure involves a complete buyout, removing Forte Biosciences from public markets and integrating its operations directly into argenx’s portfolio.

The transaction was announced on 26 July 2026 and subsequently completed on 27 August 2026. Both parties confirmed the successful closure of the agreement after the regulatory and administrative processes were finalised. The move allows argenx to fully control the strategic direction and intellectual property assets of Forte Biosciences without the obligations of public reporting. This complete acquisition represents a major step in the expansion of argenx’s capabilities in the biopharmaceutical space. The transaction is now fully completed and integrated.